Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.74 |
| ▸ | SMPD1 | P17405 | 6/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407883 | 0.89 | CNR2 (0.81) | CNR2SMPD1 | |
| SCHEMBL4416455 | 0.89 | CNR2 (0.85) | CNR2SMPD1HDAC1HDAC6CYP1A2 | |
| SCHEMBL4411452 | 0.85 | CNR2 (1.00) | CNR2SMPD1 | |
| SCHEMBL4407912 | 0.84 | CNR2 (0.98) | CNR2SMPD1 | |
| SCHEMBL4411536 | 0.84 | CNR2 (0.98) | CNR2SMPD1 | |
| SCHEMBL1042188 | 0.84 | SMPD1 (0.60) | CNR2SMPD1 | |
| SCHEMBL4408738 | 0.83 | CNR2 (0.84) | CNR2SMPD1 | |
| SCHEMBL10958244 | 0.82 | SMPD1 (0.62) | SMPD1 | |
| SCHEMBL2800438 | 0.82 | SMPD1 (0.62) | SMPD1 | |
| SCHEMBL598032 | 0.82 | SMPD1 (0.62) | SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0887340-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 1998-12-30 | — | — | EP | claimed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| WO-2002047691-A9 | PROTECTION OF NEURONS AGAINST GLUTAMATE-INDUCED DAMAGE IN GLAUCOMA AND OTHER CONDITIONS | AYOUB GEORGE S (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2002047691-A1 | PROTECTION OF NEURONS AGAINST GLUTAMATE-INDUCED DAMAGE IN GLAUCOMA AND OTHER CONDITIONS | AYOUB GEORGE S (US) | 2002-06-20 | — | — | WO | disclosed |
| US-20020077322-A1 | Protection of neurons against glutamate-induced damage in glaucoma and other conditions | AYOUB GEORGE S (US) | 2002-06-20 | — | — | US | disclosed |
| US-6017919-A | Compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2000-01-25 | — | — | US | disclosed |
| EP-0887340-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 1998-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | CNR2 2/4885SMPD1 514/4885HDAC1 2660/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CNR2 2/4885SMPD1 338/4885HDAC1 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.